Anavex Life Sciences Corp (AVXL)

[drv17]

George - I have felt that Anavex's oral presentation immediately before the final keynote address was an intentional placement so Lilly's placement would make it an alpha~omega situation.

___________________________________________________________________________
8.45 a.m OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1
, Marco Cecchi, PhD2
, Paul Maruff, PhD3
, Kristina M Kapiak4
, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
USA
9.00 a.m KEYNOTE 5
Alzheimer’s disease: from Proteinopathy to Prevention
Introduction: Zaven Khachaturian
Randall Bateman, Washington University School of Medicine, St.Louis, MO, USA_______________________________________________________________________